Determination and allelic allocation of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish population

被引:43
作者
Mrozikiewicz, PM [1 ]
Cascorbi, I [1 ]
Brockmoller, J [1 ]
Roots, I [1 ]
机构
[1] HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST KLIN PHARMAKOL,D-10098 BERLIN,GERMANY
关键词
D O I
10.1016/S0009-9236(96)90104-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The frequency of various genotypes of arylamine N-acetyltransferase (NAT2) was investigated in 248 Polish unrelated children. Allele-specific polymerase chain reaction (PCR) was applied for mutation at 341 nucleotide (nt) of NAT2 coding sequence and PCR/restriction fragment length polymorphism for the other mutations. Genotypes coded for slow acetylation in 62.9% (56.6% to 68.9%). The frequency of specific NAT2 alleles was *4(wild-type), 22.0%, *5A(341C, 481T), 5.2%; *5B(341C, 481T, 803G), 33.1%; *5C(341C, 803G), 6.0%; *6A(282T, 590A), 30.0%; *7B(282T, 857A), 3.4%; and *12A(803G), 0.2%. No mutations were found at 191, 434, and 845 nt. By a molecular-genetic procedure, genotypes *4/*6A were confirmed not to mask *6B/*13(590A/282T). *6B and *13 were absent in a composite sample representative of 826 alleles (95% confidence limits, 0% to 0.45%). Five cases of genotype-phenotype discrepancy were sequenced and their mutation allocation confirmed; 21 further genotypes were confirmed by sequencing. This first evaluation of NAT2 genes among a Slavic population should provide a basis for clinical and epidemiologic investigations of NAT2 in the Polish population.
引用
收藏
页码:376 / 382
页数:7
相关论文
共 24 条
  • [1] MOLECULAR ANALYSIS OF THE ARYLAMINE N-ACETYLTRANSFERASE POLYMORPHISM IN A SPANISH POPULATION
    AGUNDEZ, JAG
    MARTINEZ, C
    OLIVERA, M
    LEDESMA, MC
    LADERO, JM
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) : 202 - 209
  • [2] AGUNDEZ JAG, 1995, ONCOLOGY, V52, P7
  • [3] GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS
    BELL, DA
    TAYLOR, JA
    BUTLER, MA
    STEPHENS, EA
    WIEST, J
    BRUBAKER, LH
    KADLUBAR, FF
    LUCIER, GW
    [J]. CARCINOGENESIS, 1993, 14 (08) : 1689 - 1692
  • [4] MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS
    BLUM, M
    DEMIERRE, A
    GRANT, DM
    HEIM, M
    MEYER, UA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) : 5237 - 5241
  • [5] ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS
    BROCKMOLLER, J
    ROOTS, I
    [J]. CLINICAL PHARMACOKINETICS, 1994, 27 (03) : 216 - 248
  • [6] CASCORBI I, 1995, AM J HUM GENET, V57, P581
  • [7] CASCORBI I, IN PRESS PHARMACOGEN
  • [8] DROZDZ M, 1987, NEOPLASMA, V34, P481
  • [9] Evans D., 1992, Protein engineering: Proceedings of an AFRC conference on protein engineering in the agricultural and food industry, Selwyn College, Cambridge, 16-17 September 1991., P95
  • [10] PREDICTION OF PHENOTYPE FOR ACETYLATION AND FOR DEBRISOQUINE HYDROXYLATION BY DNA-TESTS IN HEALTHY-HUMAN VOLUNTEERS
    GRAF, T
    BROLY, F
    HOFFMANN, F
    PROBST, M
    MEYER, UA
    HOWALD, H
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) : 399 - 403